Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30459% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Opus Genetics's total debt was $1.20M at Mar 31, 2026. For fiscal 2025 it was $1.13M. The highest annual figure on record is $1.13M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $538.00K | – |
| FY2020 | Dec 31, 2020 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.20M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.13M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.07M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $215.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $538.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
See a number that looks wrong?